Cost effectiveness of therapeutic care of chronic obstructive pulmonary disease (copd) patients in tertiary hospitals.

Chandu Billu; Hemalatha Nelaturu; Sravya Sri Pallikonda; Jyothi Taanguturi; Trisharika Udatha; Sowjanya M; Prapurna Chandra Y

doi:10.46795/ijhcbs.v6i3.723

Billu Chandu B. Pharmacy, IV Year, Ratnam Institute of Pharmacy, spsr Nellore, Andhra Pradesh.
Nelaturu Hemalatha B. Pharmacy, IV Year, Ratnam Institute of Pharmacy, spsr Nellore, Andhra Pradesh.
Pallikonda Sravya Sri B. Pharmacy, IV Year, Ratnam Institute of Pharmacy, Pidathapolur (V & P), Muthukur (M), SPSR Nellore District-524 346, Andhra Pradesh.
Taanguturi Jyothi B. Pharmacy, IV Year, Ratnam Institute of Pharmacy, Pidathapolur (V & P), Muthukur (M), SPSR Nellore District-524 346, Andhra Pradesh.
Udatha Trisharika B. Pharmacy, IV Year, Ratnam Institute of Pharmacy, Pidathapolur (V & P), Muthukur (M), SPSR Nellore District-524 346, Andhra Pradesh.
M. Sowjanya Assistant professor, Department of Pharmacy practice, Ratnam Institute of Pharmacy, spsr Nellore, Andhra Pradesh
Y. Prapurna Chandra Principal of Ratnam Institute of Pharmacy, spsr Nellore, Andhra Pradesh.

DOI https://doi.org/10.46795/ijhcbs.v6i3.723

Abstract

Cost effectiveness of Therapeutic Care of Chronic Obstructive Pulmonary Disease (COPD) patients in tertiary hospitals. To assess the prescription pattern in Chronic Obstructive Pulmonary Disease (COPD) patients. To analyze the cost effectiveness of drugs prescribed to the Chronic Obstructive Pulmonary Disease (COPD) patients. During the study, 96 patient’s prescription both in-patient and out-patient were included for the data analysis as per the inclusion and exclusion criteria. The patients were divided in 7 groups as per the age groups. Most of the patients were found in the age group of 61 – 70 in Males and 41-50 in females. Out of 74 prescriptions analyzed that 62 were male and 12 were female. Majority of the prescription were of the age group 61-70 in males and 41-50 in females. A study conducted by Poonam Salman and coworkers in the year 2020 showed similar frequency of COPD patients in the age group of our study. The minimum number of drugs per prescription was 2 and maximum was found to be 12.Outof 74 prescriptions patients with COPD alone were 41 patients (55.4) and COPD with co morbidities were 33 patients (44.59%) and combination therapy was found to be more when compared to monotherapy. The present study which includes analysis of prescription pattern and cost of illness of a COPD patient provided a baseline data about the most commonly prescribed COPD drugs and cost effectiveness of those drugs. Out of 74 total number of prescription, the minimum cost of drug is 29.6 and maximum cost of drug is301. An Average of 5.92 drugs was prescribed for every prescription. The average cost of therapy is found to be373.28 rupees. From this study it has been concluded that majority of the COPD prescriptions in our hospital are prescribed following the gold guidelines.

Keywords: Chronic Obstructive Pulmonary Disease (COPD), prescription, cost effectiveness, therapeutic care, co-morbidities

Downloads

Download data is not yet available.

References

1. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. The Lancet. 2016 Apr 30;387(10030):1817-26.
2. Medscape. What is the worldwide prevalence of chronic obstructive pulmonary disease (COPD)? [Internet]. 2021 [cited 2021 Aug 13]. Available from: https://www.medscape.com/answers/297664-7353/what-is-the-worldwide-prevalence-of-chronic-obstructive-pulmonary-disease-copd
3. Contributor N. COPD 1: pathophysiology, diagnosis and prognosis [Internet]. Nursing Times. 2021 [cited 2021 Aug 13]. Available from: https://www.nursingtimes.net/clinical-archive/respiratory-clinical-archive/copd-1-pathophysiology-diagnosis-and-prognosis-23-03-2020/
4. Healthline. Everything You Need to Know About Chronic Obstructive Pulmonary Disease (COPD) [Internet]. 2021 [cited 2021 Aug 13]. Available from: https://www.healthline.com/health/copd
5. Wikipedia. Chronic obstructive pulmonary disease [Internet]. 2021 [cited 2021 Aug 13]. Available from: https://en.m.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease
6. Mayo Clinic. COPD - Diagnosis and treatment [Internet]. 2021 [cited 2021 Aug 13]. Available from: https://www.mayoclinic.org/diseases-conditions/copd/diagnosis_tmt/drc-20353685
7. Burkhardt R, Pankow W. The diagnosis of chronic obstructive pulmonary disease. Dtsch Arztebl Int. 2014;111(49):834–45, quiz 846.
8. Safka KA, McIvor RA. Non-pharmacological management of chronic obstructive pulmonary disease. Ulster Med J. 2015;84(1):13–21.
9. Montuschi P. Pharmacological treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2006;1(4):409–23.
10. Terzikhan N, Verhamme KMC, Hofman A, Stricker BH, Brusselle GG, Lahousse L. Prevalence and incidence of COPD in smokers and non-smokers: the Rotterdam Study. Eur J Epidemiol. 2016;31(8):785–92.
11. Torabipour A, Hakim A, Ahmadi Angali K, Dolatshah M, Yusofzadeh M. Cost analysis of hospitalized patients with chronic obstructive pulmonary disease: A state-Level Cross-sectional study. Tanaffos. 2016;15(2):75–82.
12. Susmitha N, Venkatesh P. Review on infectious diseases. Int J Indig Herbs Drugs. 2022 Jan 30:18–21.
13. Narasimha GL, Dornadula GR. A Case Report on Pleural Effusion Induced by Pulmonary Tuberculosis Reactivation. Int J Sci Res (IJSR). 2019;8(8).
14. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013 Feb 15;187(4):347–65.
15. Gunturu LN, Pamayyagari K, Dornadula GR. A Case Report on Herpes Zoster Eruption Associated with Chronic Obstructive Pulmonary Disease. Int J Ther Appl. 2020;37.
16. Vamsi V, SomaSekhar K, Sandeep R, Meghana B, Sharmila S. Case Report on Pulmonary mucormycosis. Int J Healthc Biol Sci. 2023 Nov 25:7–9.
17. Venkatesh P. Review on tuberculosis. UPI J Pharm Med Health Sci. 2022 Jan 26:15–8.
18. Srujana K, Vyshnavi P, Jessy R, Venkatesh P. Study of the utilization of antimicrobial agents at a tertiary care hospital, Nellore. UPI J Pharm Med Health Sci. 2022 Jun 28:44–50.
19. Kumar S, Madhuri G, Wilson A, George TS, Saini K, Singh R, et al. Study of prescribing pattern of drugs in chronic obstructive pulmonary disease in tertiary care teaching hospital. Indian J Pharm Pract. 2019 Jul;12(3):161.